Yourgene Health plc
(“Yourgene” or the “Group” or the “Company”)
Dr John Brown CBE confirmed as Chairman
Manchester, UK – 27 July 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, confirms the appointment of Dr John Brown CBE as Chairman to the Group with immediate effect.
Dr Brown’s appointment as Chairman was announced on 26 April 2022 and was expected to take effect at the Company’s upcoming AGM in September 2022. He has been a Non-executive Director and the Senior Independent Director of the Company since he joined Yourgene’s Board in July 2019, which has given him a deep knowledge of the business and accelerated the transition process. As a result, the Board is pleased to confirm his appointment ahead of schedule to guide the business as it enters its next stage of growth and development. Adam Reynolds will remain a Non-executive Director, as communicated in April and this transition also takes place with immediate effect.
John has over 20 years’ capital markets experience in the healthcare and life sciences sector. He is currently Chairman of Calcivis Ltd and a NED of Skylark Therapeutics Ltd. Until recently, he was Senior Independent Director of Acacia Pharma and Chairman of the Cell and Gene Therapy Catapult. Additionally, he has previous significant board experience with roles including Chairman of Axis-Shield and BTG, Senior Non-executive Director of Vectura and Chief Executive Officer of Acambis.
Adam Reynolds, Non-executive Director of the Company, said: “I am fully supportive of John’s appointment to succeed me as Chairman as Yourgene embarks on the next phase of growth. John has over 20 years’ capital markets experience in the healthcare and life sciences sector and has significant relevant Board experience. I look forward to working with John and the rest of the Board as we strive to leverage these strong foundations and deliver the shareholder returns we all desire.”
Dr John Brown, Chairman of the Group (pictured), said: “Having been part of Yourgene the past three years in the capacity of Non-Executive Director, I have seen the Company diversify and grow and look forward to working with the Board to execute on our strategic growth plan. I would like to take this opportunity to thank Adam for his stewardship and invaluable contribution to the Group over the past eight years.”
The Directors of the Company take responsibility for this announcement.
Yourgene Health plc
Lyn Rees, Chief Executive Officer
Tel: +44 (0)161 669 8122
|Cairn Financial Advisers LLP (NOMAD)|
Liam Murray / James Caithie / Ludovico Lazzaretti
|Tel: +44 (0)20 7213 0880|
|Singer Capital Markets (Joint Corporate Broker)|
Aubrey Powell / Tom Salvesen / George Tzimas
|Tel: +44 (0)20 7496 3000|
Stifel Nicolaus Europe Limited (Joint Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben Maddison
Tel: +44 (0)20 7710 7600
Walbrook PR Ltd (Media and Investor Relations)
Paul McManus / Lianne Applegarth / Alice Woodings
Tel: +44 (0)20 7933 8780 or firstname.lastname@example.org
Mob: 07980 541 893 Mob: 07584 391 303 Mob: 07407 804 654
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group’s flagship products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID-19 testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene’s geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.